What is HC Wainwright’s Estimate for AKBA FY2024 Earnings?

Akebia Therapeutics, Inc. (NASDAQ:AKBA) – HC Wainwright issued their FY2024 earnings per share estimates for Akebia Therapeutics in a research report issued on Tuesday, January 14th. HC Wainwright analyst E. Arce expects that the biopharmaceutical company will post earnings per share of ($0.34) for the year. HC Wainwright has a “Buy” rating and a $7.50 price objective on the stock. The consensus estimate for Akebia Therapeutics’ current full-year earnings is ($0.26) per share. HC Wainwright also issued estimates for Akebia Therapeutics’ Q4 2024 earnings at ($0.11) EPS, Q1 2025 earnings at ($0.11) EPS, Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at ($0.35) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at $0.42 EPS and FY2028 earnings at $1.42 EPS.

Separately, StockNews.com cut shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday.

Akebia Therapeutics Trading Up 7.3 %

Shares of NASDAQ AKBA opened at $2.07 on Friday. Akebia Therapeutics has a one year low of $0.80 and a one year high of $2.48. The business has a 50-day moving average price of $1.91 and a two-hundred day moving average price of $1.58. The firm has a market capitalization of $451.63 million, a PE ratio of -9.00 and a beta of 0.72.

Akebia Therapeutics (NASDAQ:AKBA) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.06). The business had revenue of $37.43 million during the quarter, compared to analysts’ expectations of $45.66 million. During the same period in the prior year, the firm posted ($0.08) earnings per share.

Institutional Investors Weigh In On Akebia Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of AKBA. Wellington Management Group LLP acquired a new stake in Akebia Therapeutics during the 3rd quarter valued at $534,000. BNP Paribas Financial Markets lifted its stake in shares of Akebia Therapeutics by 205.8% during the third quarter. BNP Paribas Financial Markets now owns 46,270 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 31,137 shares during the period. XTX Topco Ltd acquired a new stake in Akebia Therapeutics in the third quarter worth about $58,000. Bank of New York Mellon Corp raised its holdings in Akebia Therapeutics by 3,122.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 604,551 shares of the biopharmaceutical company’s stock worth $617,000 after purchasing an additional 585,789 shares during the last quarter. Finally, State Street Corp lifted its position in Akebia Therapeutics by 24.9% during the 3rd quarter. State Street Corp now owns 3,430,527 shares of the biopharmaceutical company’s stock valued at $4,528,000 after purchasing an additional 683,287 shares during the period. Institutional investors own 33.92% of the company’s stock.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.